Department of Biochemistry, School of Medicine, Jeju National University, Jeju, 63243, Republic of Korea.
Faculty of Biotechnology, School of Life Sciences, SARI, Jeju National University, Jeju, 63243, Republic of Korea.
Eur J Nutr. 2020 Sep;59(6):2617-2629. doi: 10.1007/s00394-019-02110-5. Epub 2019 Oct 29.
Western diet, rich in carbohydrates and fat, is said to be a major factor underlying metabolic syndrome. Interventions with prebiotics, the key modulators of the gut microbiota, have paramount impact on host-associated metabolic disorders. Herein, we investigated the effect of fungus-derived (1,3)/(1,6)-β-glucan, a highly soluble dietary fiber, on high-fat diet (HFD)-induced metabolic distress.
Male C57BL/6 J mice were fed with different diet groups (n = 11): control diet, HFD, 3 g/kg or 5 g/kg of β-glucan-incorporated HFD. At the end of experimental study period (12th week), body weight, feces weight and fecal moisture content were observed. Further, colonic motility was measured using activated charcoal meal study. Proteins extracted from liver and intestine tissues were subjected to western blot technique. Paraffin-embedded intestinal tissues were sectioned for histochemical [Periodic acid-Schiff (PAS) and Alcian blue (AB) staining] analysis. Fecal microbiota analysis was performed using MOTHUR bioinformatic software.
β-glucan consumption exhibited anti-obesity property in mice groups fed with HFD. In addition, β-glucan ameliorated HFD-induced hepatic stress, colonic motility and intestinal atrophy (reduction in colon length, goblet cells, and mucosal layer thickness). Further, β-glucan incorporation shifted bacterial community by increasing butyrate-producing bacteria such as Anaerostipes, Coprobacillus, and Roseburia and decreasing reportedly obesity-associated bacteria such as Parabacteroides and Lactococcus.
Altogether, the outcomes of this present pre-clinical animal study show β-glucan to be a promising therapeutic candidate in the treatment of HFD-induced metabolic distress. Further comprehensive research has to be conducted to brace its clinical relevance, reproducibility and efficacy for aiding human health.
富含碳水化合物和脂肪的西方饮食据称是代谢综合征的主要因素。益生菌作为肠道微生物群的关键调节剂,对宿主相关代谢紊乱具有至关重要的影响。在此,我们研究了真菌来源的(1,3)/(1,6)-β-葡聚糖(一种高度可溶的膳食纤维)对高脂肪饮食(HFD)诱导的代谢紊乱的影响。
雄性 C57BL/6J 小鼠被喂食不同的饮食组(n=11):对照饮食、HFD、3g/kg 或 5g/kg 含β-葡聚糖的 HFD。在实验研究期结束时(第 12 周),观察体重、粪便重量和粪便湿度。进一步使用活性炭餐研究测量结肠蠕动。从肝和肠组织中提取蛋白质,进行 Western blot 技术分析。对石蜡包埋的肠组织进行组织化学[过碘酸希夫(PAS)和阿利新蓝(AB)染色]分析。使用 MOTHUR 生物信息学软件进行粪便微生物组分析。
β-葡聚糖的摄入显示出对 HFD 喂养小鼠的抗肥胖作用。此外,β-葡聚糖改善了 HFD 诱导的肝应激、结肠蠕动和肠萎缩(结肠长度、杯状细胞和黏膜层厚度减少)。进一步的,β-葡聚糖的加入通过增加丁酸产生菌,如拟杆菌属、梭菌属和罗氏菌属,以及减少据报道与肥胖相关的细菌,如副拟杆菌属和乳球菌属,改变了细菌群落。
总的来说,本临床前动物研究的结果表明β-葡聚糖是治疗 HFD 诱导的代谢紊乱的有前途的治疗候选物。为了支持其临床相关性、重现性和疗效,以辅助人类健康,还需要进行进一步的全面研究。